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INTRODUCTION 
 
              Chronic Kidney disease is a clinical syndrome characterized by 
irreversible renal by dysfunction leading to excretory, metabolic and 
synthetic failure causing accumulation of non-protein nitrogenous 
substances and presents with various clinical manifestations. 
                It is a progressive loss in renal function over a period of months 
or years leading to progressive decline in glomerular filtration rate. 
                ESRD (End Stage Renal Disease) is a terminal stage of chronic 
kidney disease that without replacement therapy would result in death. 
Despite various etiologies, CKD is the final common pathway of 
irreversible destruction of nephrons resulting in alteration of ‘Milieu 
Interior’ that affects every system in the body. One such system is thyroid 
 hormonal system.  
               Patients with chronic kidney disease may have manifestations of 
thyroid dysfunction like dry skin, cold intolerance, pedal edema, fatigue, 
constipation. 
               CKD affects thyroid function in multiple ways including low 
circulating thyroid hormone concentration, altered peripheral hormone 
metabolism, disturbed binding to carrier proteins, possible reduction in 
tissue thyroid content and increased iodine stores in thyroid glands. 
CKD is a cause of non-thyroidal illness causing thyroid 
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dysfunction i.e., alteration in thyroid hormone function in the absence of 
an underlying intrinsic disorder. 
The prevalence of hypothyroidism in ESRD has been estimated 
between 0 – 9% when compared to 0.6 – 1.1% of general population 
TT3, TT4, FT3 are decreased more commonly in patients with 
Chronic renal failure. 
When hypothyroidism becomes more severe, it can cause 
reduced cardiac function and lead to progressive worsening of renal 
function. 
This study is designed to determine THE IMPACT OF THYROID 
HORMONE THERAPY ON THE CHANGES IN ESTIMATED 
GLOMERULAR FILTRATION RATE  IN CHRONIC KIDNEY 
DISEASE PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM. 
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AIMS AND OBJECTIVES 
 
• This study is undertaken to investigate the impact of thyroid 
hormone therapy on the changes in estimated glomerular filtration 
rate (eGFR) in subclinical hypothyroidism patients with chronic 
kidney disease. 
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REVIEW OF LITERATURE 
 
KIDNEY  
Each human kidney has approximately 1.3 million nephrons. Each 
individual renal tubule and its glomerulus is a unit (nephron). The size of 
the kidneys between species varies, as does the number of nephrons they 
contain.   
Each nephron is partitioned during embryologic development 
into a proximal tubule, descending and ascending limbs of the loop 
of Henle, distal tubule, and the collecting duct. These classic tubular 
segments build from subsegments lined by highly unique epithelia 
serving regional physiology.  
Between nephrons lies the renal interstitium. This region forms a 
functional space surrounding glomeruli and their downstream tubules. 
In a resting adult, the kidneys receive 1.2 to 1.3 L of blood per 
minute, or just under 25% of the cardiac output. Renal blood flow can be 
measured with electromagnetic or other types of flow meters, or it can be 
determined by applying the Fick principle to the kidney.  
The GFR in a healthy person of average size is approximately 125 
mL/min. Its magnitude correlates fairly well with surface area, but values 
in women are 10% lower than those in men even after correction for 
surface area. A rate of 125 mL/min is 7.5 L/h, or 180 L/d, whereas the 
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normal urine volume is about 1 L/d. Thus, 99% or more of the filtrate is 
normally reabsorbed. At the rate of 125 mL/min, in 1 day the kidneys 
filter an amount of fluid equal to 4 times the total body water, 15 times 
the ECF volume, and 60 times the plasma volume. 
 FACTORS AFFECTING GFR 
 
DISORDERS OF KIDNEY 
Glomerular diseases 
Tubular and interstitial diseases 
Vascular diseases 
Congenital and developmental anomalies 
Cystic diseases  
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Neoplasmas of kidney 
        These can be divided as acute and chronic diseases of kidney. 
CHRONIC DISEASES OF KIDNEY  
Chronic kidney disease (CKD) encompasses a spectrum of 
different pathophysiologic processes associated with abnormal kidney 
function and a progressive decline in glomerular filtration rate (GFR). 
 
DEFINITION 
Chronic kidney disease (CKD) is defned as kidney damage or an 
estimated glomerular fltration rate (eGFR) below 60 ml/min/1.73 m2 
persisting for 3 months or more irrespective of the cause.  
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CLASSIFICATION  
The latest 2012 KDIGO (Kidney Diseases International Guidelines 
Outcomes) CKD classification recommends detailing the cause of CKD 
and classifying into six categories related to glomerular filtration rate (G1 
to G5, with G3 split into 3a and 3b) but also based on three levels of 
albuminuria (A1, A2, and A3), each assessed according to the urinary 
albumin-creatinine ratio (in mg/g or mg/mmol in an early morning “spot” 
urine sample). The term microalbuminuria is no longer incorporated into 
this classification; the term moderate level of albuminuria is used (30 to 
300 mg/g or 2.5 to 30 mg/mmol) 
The improved classification of CKD has been of benefit to identify 
prognostic indications related to decreased kidney function as well 
as increased albuminuria. This has led to increased awareness of 
CKD as well as appreciation of the significant impact of CKD on 
health care worldwide.   
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EPIDEMIOLOGY  
It has been estimated from population survey data that at least 6% 
of the adult population has CKD at stages 1 and 2. An additional 4.5% of 
the  population is estimated to have stages 3 and 4 CKD. Five most 
frequent categories of causes of CKD, cumulatively accounting for 
greater than 90% of the CKD disease burden worldwide. The relative 
contribution of each category varies among different geographic regions. 
The most frequent cause of CKD in North America and Europe is 
diabetic nephropathy, most often secondary to type 2 diabetes mellitus. 
Patients with newly diagnosed CKD often also present with hypertension. 
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When no overt evidence for a primary glomerular or tubulointerstitial 
kidney disease process is present, CKD is often attributed to 
hypertension.  
PREVALANCE OF CKD  
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SOCIO CULTURAL BACKGROUND IN CKD 
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ETIOLOGY  
 Diabetic nephropathy 
 Glomerulonephritis 
 Hypertension-associated CKD (includes vascular and ischemic 
kidney disease and primary glomerular disease with associated 
hypertension) 
 Autosomal dominant polycystic kidney disease 
 Other cystic and tubulointerstitial nephropathy  
 These are five major categories which leads to CKD in human 
population. 
RISK FACTORS   
 Older age  
 Gender  
 Ethnicity  
 Family history of chronic kidney disease 
 Low nephron number 
 Diabetes mellitus 
 Hypertension 
 Obesity 
 High protein intake 
 Pregnancy 
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 Primary renal disease 
 Genetic renal disease 
 Urologic disorders  
 Acute kidney injury 
 Cardiovascular disease 
Albuminuria  
Hypoalbuminemia  
Anemia  
Dyslipidemia 
Hyperuricemia 
↑ ADMA level 
Hyperphosphatemia 
Smoking  
Nephrotoxins  
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RISK FACTORS AND MECHANISMS OF CKD PROGRESSION 
  
 
      
Ang II, angiotensin II; FSGS, focal and segmental 
glomerulosclerosis; PGC, glomerular capillary hydraulic pressure; 
SNGFR, single-nephron glomerular filtration  rate; TIF, tubulointerstitial 
fibrosis 
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PATHOPHYSIOLOGY OF UREMIC SYNDROME  
1. Those consequent to the accumulation of toxins that normally 
undergo renal excretion, including products of protein metabolism;  
2. Those consequent to the loss of other kidney functions, such as 
fluid and electrolyte homeostasis and hormone regulation; and 
3. Progressive systemic inflammation and its vascular and nutritional 
consequences.  
COMPLICATIONS OF CHRONIC KIDNEY DISEASE AND 
UREMIA FLUID, ELECTROLYTE, AND ACID-BASE 
DISORDERS  
Sodium and Water Homeostasis: 
 In most patients with stable CKD, 
the total-body content of sodium and water is modestly increased, 
although this may not be apparent on clinical examination.  
Potassium Homeostasis: 
 In CKD, the decline in GFR is not necessarily accompanied by a 
parallel decline in urinary potassium excretion, which is predominantly 
mediated by aldosterone-dependent secretion in the distal nephron. 
Another defense against potassium retention in these patients is 
augmented potassium excretion in the GI tract. However later this 
protection will lost.  
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 Metabolic Acidosis  
Metabolic acidosis is a common disturbance in 
advanced CKD. The majority of patients can still acidify the urine, 
but they produce less ammonia and, therefore, cannot excrete the 
normal quantity of protons in combination with this urinary buffer. 
Hyperkalemia, if present, further depresses ammonia production. 
DISORDERS OF CALCIUM AND PHOSPHATE METABOLISM 
The principal complications of abnormalities of calcium and 
phosphate metabolism in CKD occur in the skeleton and the vascular bed, 
with occasional severe involvement of extra osseous soft tissues. It is 
likely that disorders of bone turnover and disorders of vascular and soft 
tissue calcification are related to each other. 
Bone Manifestations of CKD  
The major disorders of bone disease can be 
classified into those associated with high bone turnover with increased 
PTH levels (including osteitis fibrosa cystica, the classic lesion of 
secondary hyperparathyroidism) and low bone turnover with low or 
normal PTH levels (adynamic bone disease and osteomalacia) 
Calcium, Phosphorus, and the Cardiovascular System  
Recent epidemiologic evidence has shown a strong association 
between hyperphosphatemia and increased cardiovascular mortality rate 
in patients with stage 5 CKD and even in patients with earlier stages of 
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CKD. Hyperphosphatemia and hypercalcemia are associated with 
increased vascular calcification, but it is unclear whether the excessive 
mortality rate is mediated by this mechanism.  
Calciphylaxis (calcific uremic arteriolopathy) is a devastating 
condition seen almost exclusively in patients with advanced CKD. It is 
heralded by livedo reticularis and advances to patches of ischemic 
necrosis, especially on the legs, thighs, abdomen, and breasts 
CARDIO VASCULAR ABNORMALITIES  
Cardiovascular disease is the leading cause of morbidity and 
mortality in patients at every stage of CKD. The incremental risk of 
cardiovascular disease in those with CKD compared to the age- and sex-
matched general population ranges from 10- to 200-fold, depending on 
the stage of CKD. Between 30 and 45% of patients reaching stage 5 CKD 
already have advanced cardiovascular complications. As a result, most 
patients with CKD succumb to cardiovascular disease  before ever 
reaching stage 5 CKD.  
Ischemic Vascular Disease  
The presence of any stage of CKD is a 
 major risk factor for  ischemic cardiovascular disease, including 
occlusive, cerebrovascular, and peripheral vascular disease. The  
increased prevalence of vascular disease in CKD patients derives from 
both traditional (“classic”) and nontraditional (CKD-related) risk 
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factors. Traditional risk factors include hypertension, hypervolemia, 
dyslipidemia, sympathetic over activity, and hyperhomocysteinemia. 
The CKD-related risk factors comprise anemia, hyperphosphatemia, 
hyperparathyroidism, increased FGF-23, sleep apnea, and generalized 
inflammation.  
Heart Failure  
Abnormal cardiac function secondary to myocardial 
ischemia, left ventricular hypertrophy, and frank cardiomyopathy, 
in combination with the salt and water retention that can be seen 
with CKD, often results in heart failure or even pulmonary edema. 
Heart failure can be a consequence of diastolic or systolic dysfunction, or 
both.  
Hypertension and Left Ventricular Hypertrophy  
Hypertension is one of the most common complications of CKD. It 
usually develops early during the course of CKD and is associated with 
adverse outcomes, including the development of ventricular hypertrophy 
and a more rapid loss of renal function. Many studies have shown 
a relationship between the level of blood pressure and the rate of 
progression of diabetic and nondiabetic kidney disease. Left ventricular 
hypertrophy and dilated cardiomyopathy are among the 
strongest risk factors for cardiovascular morbidity and mortality 
in patients with CKD. 
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Pericardial Disease  
Chest pain with respiratory accentuation, accompanied by a friction 
rub, is diagnostic of pericarditis. Classic electrocardiographic 
abnormalities include PR-interval depression and diffuse ST-segment 
elevation. Pericarditis can be accompanied by pericardial effusion that is 
seen on echocardiography and can rarely lead to tamponade.  
HEMATOLOGIC ABNORMALITIES                                                     
Anemia  
A normocytic, normochromic anemia is observed as early as 
stage 3 CKD and is almost universal by stage 4. The primary cause in 
patients with CKD is insufficient production of erythropoietin (EPO) 
by the diseased kidneys. 
Abnormal Hemostasis  
Patients with later stages of CKD may have 
a prolonged bleeding time, decreased activity of platelet factor III, 
abnormal platelet aggregation and adhesiveness, and impaired 
prothrombin consumption. Clinical manifestations include an increased 
tendency to bleeding and bruising, prolonged bleeding from surgical 
incisions, menorrhagia, and GI bleeding.  
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 NEUROMUSCULAR ABNORMALITIES 
Central nervous system (CNS), peripheral, and autonomic 
neuropathy as well as abnormalities in muscle structure and function are 
all well recognized complications of CKD. Subtle clinical manifestations 
of uremic neuromuscular disease usually become evident at stage 3 CKD. 
Early manifestations of CNS complications include mild disturbances 
in memory and concentration and sleep disturbance. Neuromuscular 
irritability, including hiccups, cramps, and twitching. 
GASTROINTESTINAL AND NUTRITIONAL ABNORMALITIES 
Uremic fetor, a urine-like odor on the breath, derives from the 
breakdown of urea to ammonia in saliva and is often associated with an 
unpleasant metallic taste (dysgeusia). Gastritis, peptic disease, and 
mucosal ulcerations at any level of the GI tract occur in uremic patients 
and can lead to abdominal pain, nausea, vomiting, and GI bleeding. These 
patients are also prone to constipation, which can be worsened 
by the administration of calcium and iron supplements. The retention 
of uremic toxins also leads to anorexia, nausea, and vomiting.   
ENDOCRINOLOGICAL COMPLICATIONS 
Chronic kidney disease (CKD), end-stage renal disease (ESRD), 
and kidney transplantation all affect the endocrine system in ways that 
encompass a wide variety of syndromes and clinical disorders. The 
kidney is a potent endocrine organ, 
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a key modulator of endocrine function, and an important target for 
hormonal action. Thus, alterations in signal-feedback mechanisms and in 
production, transport, metabolism, elimination, and protein binding of 
hormones occur rather commonly in these conditions. As a direct 
consequence, the uremic state is associated with abnormalities in the 
synthesis or action of many hormones, including those of the pituitary 
gland (e.g., prolactin, growth hormone [GH]) and those of the pancreas 
INSULIN RESISTANCE 
Causes 
Insulin secretion abnormalities 
 Hyperparathyroidism 
 Vitamin D deficiency 
Insulin resistance 
 Anemia  
 Metabolic acidosis 
  Inﬂammation 
 Oxidativestress            
 Muscleloss           
 Increased fat mass 
 Physicalinactivity 
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Consequences 
 Dyslipidemia 
 Sodiumretention 
 Vascularcalcifcation 
 Musclewasting 
 Hyperuricemia 
 Reninactivation 
 Hypertension and cardiovascular disease  
HYPOTHALAMIC PITUTRIC AXIS  
In physiologic conditions, both the kidneys and the thyroid are 
intimately related: Whereas thyroid hormones are necessary 
for growth and development of the kidneys and for the maintenance of 
water and electrolyte homeostasis, the kidneys are 
involved in the metabolism and clearance of thyroid hormones. 
Thus, it is not surprising that a decline of kidney function is accompanied 
by changes in the synthesis, secretion, metabolism, 
and elimination of thyroid hormones, leading to characteristic 
disturbance of thyroid physiologic function 
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DERMATOLOGIC ABNORMALITIES 
Abnormalities of the skin are prevalent in progressive CKD. 
Pruritus is quite common and one of the most vexing manifestations of 
the uremic state. In advanced CKD, even on dialysis, patients may 
become more pigmented, and this is felt to reflect the deposition of 
retained pigmented metabolites, or urochromes. A skin condition unique 
to CKD patients called nephrogenic fibrosing dermopathy consists of 
progressive subcutaneous induration, especially on the arms and legs. 
APPROACH TO CKD 
HISTORY AND CLINICAL  
History of hypertension (which can cause CKD or more commonly 
be a consequence of CKD), diabetes mellitus, abnormal urinalyses, and 
problems with pregnancy such as preeclampsia or early pregnancy loss.  
A careful drug history should be elicited: patients may not volunteer use 
of analgesics, for example. Other drugs to consider include nonsteroidal 
anti-inflammatory agents, cyclooxygenase-2 (COX-2) inhibitors, 
antimicrobials, chemotherapeutic agents, antiretroviral agents, proton 
pump inhibitors, phosphate-containing bowel cathartics, and lithium.  
History regarding appetite, weight loss, nausea, hiccups, peripheral 
edema, muscle cramps, pruritus, and restless are especially helpful to 
found uremic syndrome.  A careful family history of kidney disease, 
together with assessment of manifestations in other organ systems such as 
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auditory, visual, and integumentary, may lead to the diagnosis of a 
heritable form of CKD (e.g., Alport or Fabry disease, cystinosis) 
Blood pressure  
Funduscopy   
Precordial examination (left ventricular heave, a fourth heart sound)  
Funduscopy is important in the diabetic patient, because 
it may show evidence of diabetic retinopathy, which is associated with 
nephropathy.  
Other physical examination manifestations of CKD 
include edema and sensory polyneuropathy. The finding of asterixis 
or a pericardial friction rub not attributable to other causes usually 
signifies the presence of the uremic syndrome. 
LABORATORY INVESTIGATION  
The Modification of Diet in Renal Disease GFR (MDRD GFR) 
calculation is a creatinine-based equation used to estimate a patient’s 
GFR. 
eGFR = 175 x (SCr)-1.154 x (age)-0.203 x 0.742 [if Female] x 1.212 [if Black] 
It requires that the patient have a stable creatinine level. 
The equation depends on its ability to predict a patient’s normal 
creatinine production level. It has been validated in patients with CKD, 
African-Americans, Caucasians, and females. 
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RELATIONSHIP BETWEEN GFR AND PROTENURIA 
 
 
  
25 
 
Urine protein excretion: 
Heavy proteinuria is associated with progression of renal disease, 
and the amount of proteinuria serves as an indicator of the severity of 
disease in certain glomerulonephritis. 
It can be assessed in a 24-hour urine collection or by calculating 
the urine protein to creatinine ratio in a spot collection (see chapter on 
proteinuria). 
Evaluation of anemia: 
Complete blood cell count  
Ferritin and transferrin saturation levels are required to help guide 
the treatment of anemia. The Kidney Disease Outcomes Quality Initiative 
(KDOQI) work group recommends a ferritin level >100 ng/mL and a 
transferrin saturation >20% in predialysis CKD patients.  
PTH, calcium, phosphorus, and 25-OH vitamin D levels should 
be measured to assist in directing the management of renal 
osteodystrophy. For stages 3 and 4 CKD, the KDOQI work group 
recommends maintaining corrected calcium in the “normal” range for the 
laboratory used and a phosphorus value between 2.7 and 4.6 mg/dL. 
Measurement of intact PTH is recommended at least every 6 to 12 
months. 
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Diabetic workup includes FBS, PPBS  
THYROID FUNCTION TEST includes TSH, free T4, free T3, 
total T4, total T3. A lipid panel should be checked in all CKD patients at 
initial office visit and annually. Patients with nephrotic syndrome are 
particularly susceptible to dyslipidemia. It is generally recommended that 
triglyceride level is kept below 200 mg/dL. 
  Hepatitis B and C and HIV serologies may help diagnose the 
underlying cause of the patient’s CKD (e.g., membranoproliferative 
glomerulonephritis secondary to Hepatitis C-induced cryoglobulinemia or 
HIV nephropathy). Hepatitis B titers are also useful to determine which 
patients need to be immunized against the disease as CKD progresses.  
An antinuclear antibody can suggest the presence of autoimmune 
disease as the cause of the patient’s CKD, and high titers may warrant 
additional workup such as complement levels and extractable nuclear 
antibody screen.  
Serum and urine protein electrophoresis, along with 
immunofixation, are useful diagnostic tools to evaluate for 
paraproteinemia and related renal disorders such light chain deposition 
disease, cast nephropathy, and amyloidosis.  
A renal ultrasound is usually performed after the initial visit for 
several reasons. It helps to delineate renal anatomy and verify the 
presence of two normal sized kidneys. It is useful to rule out obstruction. 
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It may detect abnormalities such as nephrocalcinosis/nephrolithiasis. 
It aids in the detection of cysts or renal cell cancers. Renal cell 
malignancies are more common in patients with CKD. 
Abnormally large kidneys (>13 cm) may suggest the presence of certain 
disease such as diabetic nephropathy, HIV-associated nephropathy, 
infiltrative disorders, interstitial nephritis, and so forth. 
 A Doppler study of the renal arteries can help rule out renal 
artery disease in a patient with resistant or difficult-to-control 
hypertension. 
A kidney biopsy is indicated in the setting of proteinuria and 
hematuria or unexplained rise in serum creatinine. 
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RECOMMENDATIONS TO SLOWER THE DISEASE 
PROGRESSION 
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HYPERTENSION 
The blood pressure goal is <130/80 mm Hg. Diuretics, beta-
blockers, angiotensin-converting enzyme (ACE) inhibitors and/or 
angiotensin-receptor blockers (ARB), calcium channel blockers, alpha-
blockers, alpha-2 agonists, aldosterone receptor antagonists, and 
vasodilators are all used to achieve blood pressure goals. 
ACE inhibitors and/or ARBs are useful in patients with proteinuria. 
ACE inhibitors and ARBs classically lower intraglomerular pressure, thus 
protecting the kidneys from disease progression. 
A renal function panel should be checked 1 to 2 weeks after starting 
treatment with ACE inhibitors or ARBs. A 30% increase in creatinine is 
considered acceptable, although often hyperkalemia can limit the use of 
these medications.  
Edema and Volume Overload 
Edema and volume overload are frequently seen in CKD, 
especially in the setting of nephrotic range proteinuria, congestive heart 
failure, pulmonary dysfunction, sleep apnea, and GFR <40 mL/min. 
Diuretics are an effective therapy in the management of hypertension 
and edema in CKD. The effectiveness of thiazide diuretics is reduced in 
patients with GFR<40 mL/min. Loop diuretics are useful in patients with 
low GFRs, but their effectiveness may be more limited in patients with a 
low serum albumin. A reasonable starting dose for a loop diuretic in a 
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patient with CKD is furosemide 40 mg PO bid or bumetanide 1 mg PO 
bid. A new steady state will be reached within 1 to 2 weeks. 
Sodium restriction is also an essential component of management of 
edema 
Anemia and Iron Deficiency 
If iron deficiency is diagnosed, appropriate gastrointestinal workup 
should be considered. Iron deficiency, even in the absence of anemia, is 
associated with neurological dysfunction, restless legs syndrome, fatigue, 
hair loss, and even worsening of cardiac dysfunction.If no 
contraindications exist, iron replacement should begin via the 
oral route, which is the preferred first line of treatment. 
Commonly  ferrous sulfate PO bid–tid used. 
Iron is best absorbed on an empty stomach and in an acid 
environment. Patients treated with antireflux medications will not absorb 
iron as efficiently as patients not taking these drugs. 
If patient has suboptimal response to oral iron or if the patient is unable 
to tolerate the treatment, then intravenous iron should be considered. 
There are several options for intravenous iron—iron dextran, iron 
sucrose, ferric gluconate, or ferumoxytol. The lowest number of adverse 
events has been associated with iron sucrose. 
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Erythropoiesis-stimulating agents (ESAs): 
Erythropoietin replacement or ESA is necessary once hemoglobin 
levels fall to <10 g/dL. The current Food and Drug Administration 
guidelines recommend that ESA should be used only to prevent blood 
transfusion and not to treat symptoms such as fatigue and decreased 
energy. Currently approved ESAs include epoetin alfa and darbepoetin 
alfa. A typical starting dose of epoetin alfa is 50 to 100 units/kg 
subcutaneously every week or darbepoetin alfa 40 mcg subcutaneously 
every 2 weeks.  
Higher hemoglobin levels are not necessarily beneficial to patients. 
As hemoglobin levels >13 g/dL during ESA therapy have been associated 
with increased rates of blood clots, heart attacks, strokes, and death, the 
complete blood cell count should be monitored at least monthly while 
administering an ESA to avoid exceeding that level.  
Renal Osteodystrophy/Secondary Hyperparathyroidism 
The management of ROD is complex and involves reduction of 
phosphorus in diet, use of phosphate binders, and appropriate use of 
vitamin D analogs. 
Dietary restriction: 
It is generally recommended to restrict phosphorus intake to 800 
to1200 mg/d.  
 
  
32 
 
Phosphorus binders: 
Phosphorus binders are primarily calcium compounds (calcium 
carbonate or acetate). Aluminium compounds are rarely used because of 
risk of toxicity. Other binders, such as sevelamer hydrochloride or 
carbonate, are not approved for use in predialysis CKD.  
Because of concern of excessive calcium loading and vascular 
calcification, it is generally recommended to limit the amount of 
elemental calcium no more than 2000 mg/d. 
Vitamin D analogs: 
Active vitamin D (1,25-dihydroxycholecalciferol also known as 
“calcitriol”) provides a feedback mechanism to the parathyroid gland to 
reduce PTH production and secretion. The typical starting dose for 
calcitriol is 0.25 mcg PO daily, for paricalcitol it is 1 mcg PO daily or 2 
mcg PO three times a week, and for doxercalciferol it is 1 mcg/d. Serum 
calcium and phosphorus should be evaluated within 2 to 4 weeks of 
therapy initiation to check for hypercalcemia and hyperphosphatemia.  
Metabolic Acidosis 
Metabolic acidosis can lead to decreased albumin production, 
increased calcium resorption from bone, and worsening of SHPT. 
The best available option to treat acidosis is sodium bicarbonate 650 
to 1300 mg PO bid–tid. A 650-mg tablet contains 7.6 mEq of 
bicarbonate. Maintaining bicarbonate levels above 22 mEq/L will help 
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preserve bone histology and lessen the impact of acidosis on protein 
catabolism. Correction of acidosis will also help in the management of 
hyperkalemia. A recent randomized controlled study also noted that 
treatment with sodium bicarbonate decelerated the rate of progression 
to ESRD, while improving nutritional parameters in CKD patients.  
Hyperlipidemia 
CKD patients should be considered to be in the highest risk group 
for coronary artery disease. The updated National Cholesterol Education 
Program Adult Treatment Program (NCEP ATP) III guidelines for 
cholesterol management recommend a low-density lipoprotein cholesterol 
goal of <100 mg/dL for high-risk patients defined as those with 
established CHD or coronary heart disease risk equivalents. 
Lifestyle modifications are recommended for LDL 100 to 130 
mg/dL as initial line of therapy. Medications are recommended for those 
with LDL above 130 mg/dL or those failing lifestyle modifications. 
Statins are first-line agents in CKD. 
Hypertriglyceridemia is treated using lifestyle and dietary 
modifications as well as medications with goal of triglycerides of <200 
mg/dL. 
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Hyperkalemia 
Hyperkalemia is a potentially life-threatening complication of 
CKD. 
Dietary restriction: Patients should be counseled regarding the 
restriction of high-potassium foods in their diet. High potassium content 
is seen in all types of foods, but the common ones are citrus fruits/juices; 
bananas; watermelons; dried foods such as raisins, prunes, and dates; 
vegetables such as tomatoes, potatoes, and broccoli; and other food 
products such as milk.   
Hyperuricemia 
Hyperuricemia is associated with metabolic syndrome and 
increased risk for cardiovascular disease and all-cause mortality.27 
Hyperuricemia is prevalent in CKD due to decreased uric acid excretion 
as well as the use of diuretics, which further decrease uric acid 
excretion.  
Treatment of hyperuricemia and gout involves use of steroids or 
colchicine to treat acute flares.  Once acute flare has been treated, it is 
recommended that a xanthine oxidase inhibitor such as allopurinol or 
febuxostat be used to lower uric acid levels. 
Initiation of Renal Replacement Therapy in ESRD patients. 
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THYROID  
ANATOMY  
The thyroid is an endocrine gland which consists of two lobes. 
They connected by an isthmus. It is located anterior to the trachea 
between the cricoid cartilage and the suprasternal notch. The normal 
weight of thyroid is 12–20 g . It is highly vascular, and soft in 
consistency.  
PHYSIOLOGY  
The thyroid gland produces two related hormones, thyroxine (T4) 
and triiodothyronine (T3). Acting through thyroid hormone receptors α 
and β,  
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PROPERTIES OF HORMONES 
 
these hormones play a critical role in cell differentiation during 
development help maintain thermogenic and metabolic homeostasis in the 
adult. 
SYNTHESIS   
The thyroid axis is a classic example of an endocrine feedback 
loop. Hypothalamic TRH stimulates pituitary production of TSH, which, 
in turn, stimulates thyroid hormone synthesis and secretion. Thyroid 
hormones act via negative feedback predominantly through thyroid 
hormone receptor β2 (TRβ2) to inhibit TRH and TSH production. 
The “set-point” in this axis is established by TSH. 
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T4 and T3 are the two principle hormones produced by thyroid 
gland in our body. Initially iodine is absorbed in the gut and is converted 
to iodide and transported in the blood. It is then actively transferred                
into the thyroid cell by “Iodide trapping”. The trapped iodide is 
“Oxidized” to iodine and combines with tyrosine to form Mono 
iodotyrosine (MIT) and Diiodotyrosine (DIT) respectively Oxidation, 
iodination and coupling reactions are catalyzed by “Thyroid peroxidase”. 
Thyroid hormone thus produced is bound with thyroglobulin until 
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secreted. Once secreted in the blood, it is transported in two forms. One is 
bound form, in which T3 and T4 are bound form, in which T3 and T4 are 
bound to plasma proteins namely thyroid binding globulin, prealbumin 
and albumin. 
Thyrotropin Releasing Hormone (TRH)  
TRH is a very small tripeptide amide L-pyroglutamyl-Lhistidyl-L-
prolineamide (L-PHP). TRH release is inﬂuenced by thyroid hormones in 
circulation and control from the hypothalamus. Once TRH is released 
from the hypothalamus, it travels to the anterior pituitary, where it 
interacts with TRH receptors (C-phosphoinositide pathway) to cause 
the release of thyroid stimulating hormone (TSH) 
Thyroid Stimulating Hormone (TSH) 
TSH is a 28 to 30 kDa glycoprotein subset of the cystineknot 
growth factor super family. It is produced from the basophilic cells of the 
anterior pituitary gland. After being released from the anterior pituitary, 
TSH travels to the thyroid gland and binds with TSH receptors on thyroid 
cells. Tis physiological action activates the second messenger 
pathway resulting in thyroid gene expression and the release 
of T3/T4. 
THYROID BINDING PROTEINS  
T4 is secreted from the thyroid gland in about twentyfold excess 
over T3. Both hormones are bound to plasma proteins, including 
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thyroxine- binding globulin (TBG), transthyretin (TTR, formerly known 
as thyroxinebinding prealbumin, or TBPA), and albumin. The plasma-
binding proteins increase the pool of circulating hormone, delay hormone 
clearance, and may modulate hormone delivery to selected tissue sites. 
The concentration of TBG is relatively low (1–2mg/dL), but because of 
its high affinity for thyroid hormones (T4 > T3), it carries about 80% of 
the bound hormones. Albumin has relatively low affinity for thyroid 
hormones but has a high plasma concentration (~3.5 g/dL), and it binds 
up to 10% of T4 and 30% of T3. TTR carries about 10% of T4 but little 
T3. 
Disorders of the thyroid gland  
overproduction of thyroid hormones (thyrotoxicosis)  
glandular destruction or/and hormone deficiency (hypothyroidism) 
neoplasm of thyroid gland  
HYPOTHYROIDISM It is a condition caused by a structural or 
functional derangement that interferes with the production of thyroid 
hormone. Iodine deficiency remains a common cause of hypothyroidism 
worldwide. 
 
 
 
 
  
40 
 
 
IODINE  NUTRITION 
 
 
 
 
 
 
 
 
 
 
 
  
41 
 
CAUSES  OF  HYPOTHYROIDISM 
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Classification  
Autoimmune hypothyroidism may be associated with 
a goiter (Hashimoto’s, or goitrous thyroiditis) or, at the later stages 
of the disease, minimal residual thyroid tissue (atrophic thyroiditis). 
Because the autoimmune process gradually reduces thyroid function, 
there is a phase of compensation when normal thyroid hormone levels 
are maintained by a rise in TSH. Although some patients may have 
minor symptoms, this state is called subclinical hypothyroidism. Later, 
unbound T4 levels fall and TSH levels rise further; symptoms become 
more readily apparent at this stage (usually TSH >10 mIU/L), which is 
referred to as clinical hypothyroidism or overt hypothyroidism. 
Prevalence  
The mean annual incidence rate of autoimmune hypothyroidism is 
up to 4 per 1000 women and 1 per 1000 men. It is more common in 
certain populations, such as the Japanese, probably because of genetic 
factors and chronic exposure to a high-iodine diet. The mean age at 
diagnosis is 60 years, and the prevalence of overt hypothyroidism 
increases with age. Subclinical hypothyroidism is found in 6–8% of 
women (10% over the age of 60) and 3% of men. The annual risk of 
developing clinical hypothyroidism is about 4% when subclinical 
hypothyroidism is associated with positive TPO antibodies. 
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CLINICAL FEATURES  
SYMPTOMS  
 Tiredness, 
 Weakness 
 Dryskin 
 Feeling cold 
 Hair loss 
 Difficulty concentrating and poor memory 
 Constipation 
 Weight gain with poor appetite 
 Dyspnea 
 Hoarse voice 
 Menorrhagia(later oligo menorrhea or amenorrhea) 
 Paresthesia 
 Impaired hearing  
SIGNS 
 Dry coarse skin  
 cool peripheral extremities 
 Puffy face, hands, and feet (myxedema) 
 Diffuse alopecia 
 Bradycardia 
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 Peripheral edema 
 Delayed tendon reflex relaxation 
 Carpal tunnel syndrome 
 Serous cavity effusions 
Skin and Appendages 
Hypothyroidism causes an accumulation of hyaluronic 
acid that alters the composition of the ground substance 
in the dermis and other tissues. This material is hygroscopic, producing 
the mucinous edema that is responsible for the thickened features and 
puffy appearance (myxedema) with full-blown hypothyroidism. 
Myxedematous tissue is characteristically boggy and non pitting and is 
apparent around the eyes.  
Cardiovascular System 
The cardiac output at rest is decreased because of reduction 
in both stroke volume and heart rate, reﬂecting loss of 
the inotropic and chronotropic effects of thyroid hormones. Peripheral 
vascular resistance at rest is increased, and blood volume is reduced. 
These hemodynamic alterations cause narrowing of pulse pressure, 
prolongation of circulation time, and decrease in blood ﬂow to the tissues. 
The reduction in cutaneous circulation is responsible for the coolness and 
pallor of the skin and the sensitivity    to cold. 
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Respiratory System 
Hypothyroidism affects breathing by actions on the central 
regulation of respiration as well as the innervation and function of the 
respiratory muscles, upper airways, and tongue. Pleural effusions usually 
are evident only on radiologic examination. 
Alimentary System 
Although most patients experience a modest gain in weight, 
appetite is usually reduced. The weight gain that occurs is caused partly 
by retention of ﬂuid by the hydrophilic glycoprotein deposits in the 
tissues, but generally does not exceed 10% of body weight. Peristaltic 
activity is decreased and, together with the decreased food intake, is 
responsible for the frequent complaint of constipation.  
Central and Peripheral Nervous Systems 
Thyroid hormone is essential for the development of the 
central nervous system. Deficiency in fetal life or at birth impairs 
neurologic development, including hypoplasia of cortical neurons with 
poor development of cellular processes, retarded myelination, and 
reduced vascularity. If the deficiency is not corrected in early postnatal 
life, the damage is irreversible.  
Muscular System 
Stiffness and aching of muscles are common in hypothyroidism 
and are worsened by cold temperatures. Delayed muscle contraction and 
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relaxation cause slowness of movement and delayed tendon jerks. Muscle 
mass may be reduced or enlarged due to interstitial myxedema.  
Skeletal System: Calcium and Phosphorus Metabolism 
Thyroid hormone is essential for normal growth and maturation of 
the skeleton, and growth failure is due both to impaired general protein 
synthesis and to a  reduction in growth hormone, but especially of 
insulin-like growth factor 1. 
Renal Function: Water and Electrolyte Metabolism 
 
Reversible reductions in renal blood ﬂow, glomerular filtration 
rate, and tubular reabsorption are seen in hypothyroidism. Blood urea 
nitrogen and serum creatinine levels are normal, but uric acid levels may 
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be increased. Urine ﬂow is reduced, and delay in the excretion of a water 
load   may  result  in  of  the   normal  diurnal  pattern of urine excretion.  
Hyponatremia is the commonest electrolyte derangement in 
hypothyroid patients. Hyponatremia appears in 45% of hypothyroid 
patients who have elevated serum creatinine, but in less than a quarter 
(21%) of those with normal creatinine levels. It is mainly due to a 
reduction in GFR causing diminished water delivery to 
the distal tubular segments. This becomes evident after 
water load, although ADH may be appropriately suppressed. Other 
possible mechanism of hypothyroidism induced hyponatremia is an 
inappropriate ADH secretion syndrome (SIADH)-like disorder 
Hematopoietic System 
In response to the diminished oxygen requirements and 
decreased production of erythropoietin, the red blood cell 
mass is decreased; this is evident in the mild normocytic, 
normochromic anemia that often occurs. Less commonly, the anemia is 
macrocytic, sometimes from deficiency of vitamin B12. Conversely, 
overt and subclinical hypothyroidism is present in  12%  and  15%  of  
patients,  respectively, with  pernicious  anemia.  
Pituitary and Adrenocortical Function 
In long-standing primary hypothyroidism, hyperplasia of the 
thyrotropes may cause the pituitary gland to be  enlarged. This feature 
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can be detected   radiologically as an increase in the volume of the 
pituitary fossa. Rarely, the pituitary enlargement compromises the 
function of other pituitary cells and causes pituitary insufficiency or 
visual  field defects. Patients with severe hypothyroidism may have 
increased serum prolactin levels, stimulated by the elevation in 
thyrotropin-releasing hormone (TRH). 
Reproductive Function 
In both sexes, thyroid hormones inﬂuence sexual development and 
reproductive function. Infantile hypothyroidism, if untreated, leads to 
sexual immaturity, and juvenile hypothyroidism causes a delay in the 
onset of puberty followed by anovulatory cycles. Paradoxically, primary 
hypothyroidism may also rarely cause precocious sexual development 
and galactorrhea, presumably due to “spillover” of elevated TSH 
stimulating the luteinizing hormone (LH) receptor and elevated TRH 
initiating excess prolactin release.  
Energy Metabolism: Protein, Carbohydrate, and Lipid Metabolism 
The decrease in energy metabolism and heat production is 
reﬂected in a low basal metabolic rate, decreased appetite, cold 
intolerance, and slightly low basal body temperature. Both the synthesis 
and the degradation of   protein are decreased, the latter especially so, 
with the result that nitrogen balance is usually slightly positive. The 
  
49 
 
decrease in protein synthesis is reﬂected in retardation of both skeletal 
and soft tissue growth. 
Hypothyroidism is associated with a reduction in glucose disposal 
to skeletal  muscle and adipose tissue. Thyroid hormone has been shown 
to stimulate expression of the insulin-sensitive glucose transporter 
(GLUT4), and the levels of  this  transporter  are  reduced  in  
hypothyroidism. Both the synthesis and the degradation of lipid are 
depressed in hypothyroidism. Degradation, however, is reduced to a 
greater extent, with a net effect of accumulation of LDL and triglycerides. 
 
TPOAb+, thyroid peroxidase antibodies present. TPOAb-, thyroid 
peroxidase antibodies not present. TSH, thyroid-stimulating hormone. 
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PHYSICAL EXAMINATION 
In addition to the examination of the thyroid itself, the physical 
examination should include a search for signs of abnormal thyroid 
function and the extrathyroidal features of ophthalmopathy and 
dermopathy. 
 Examination of the neck begins by inspecting the seated 
patient from the front and side and noting any surgical scars, obvious 
masses, or distended veins. The thyroid can be palpated with both 
hands from behind or while facing the patient, using the thumbs to 
palpate each lobe. 
If the lower borders of the thyroid lobes are not clearly felt, a goiter 
may be retrosternal. Large retrosternal goiters can cause venous 
distention over the neck and difficulty breathing, especially when the 
arms are raised (Pemberton’s sign). With any central mass above the 
thyroid, the tongue should be extended, as thyroglossal cysts then move 
upward. The thyroid examination is not complete without assessment for 
lymphadenopathy in the supraclavicular and cervical regions of the neck. 
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LABORATORY EVALUATION 
Measurement of Thyroid Hormones  
The enhanced sensitivity and specificity of TSH assays have 
greatly improved laboratory assessment of thyroid function. Because 
TSH levels change dynamically in response to alterations of T4 and T3, a 
logical approach to thyroid testing is to first determine whether TSH is 
suppressed, normal, or elevated. With rare exception, a normal TSH level 
excludes a primary abnormality of thyroid function. This strategy 
depends on the use of immunochemiluminometric assays (ICMAs) for 
TSH that are sensitive enough to discriminate between the lower limit of 
the reference range and the suppressed values that occur with 
thyrotoxicosis. Extremely sensitive (fourth-generation) assays can detect 
TSH levels ≤0.004 mIU/L, but, for practical purposes, assays sensitive to 
≤0.1 mIU/L are sufficient. The widespread availability of the TSH ICMA 
has rendered the TRH stimulation test obsolete, because the failure 
of TSH to rise after an intravenous bolus of 200–400 μg TRH has the 
same implications as a suppressed basal TSH measure 
Total thyroid hormone levels are elevated when TBG is increased 
due to estrogens (pregnancy, oral contraceptives, hormone therapy, 
tamoxifen, selective estrogen receptor modulators, inflammatory liver 
disease) and decreased when TBG binding is reduced (androgens, 
nephrotic syndrome). Genetic disorders and acute illness can also 
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cause abnormalities in thyroid hormone binding proteins, and various 
drugs (phenytoin, carbamazepine, salicylates, and nonsteroidal anti 
inflammatory drugs [NSAIDs]) can interfere with thyroid hormone 
binding. Because unbound thyroid hormone levels are normal and the 
patient is euthyroid in all of these circumstances, assays that measure 
unbound hormone are preferable to those for total thyroid hormones d by 
ICMA. 
The unbound T4 level is sufficient to confirm 
thyrotoxicosis, but 2–5% of patients have only an elevated T3 level 
(T3 toxicosis). Thus, unbound T3 levels should be measured in patients 
with a suppressed TSH but normal unbound T4 levels. suppressed TSH 
level, particularly <0.01 mIU/L, usually indicates thyrotoxicosis. 
However, subnormal TSH levels between 0.01 and 0.1 mIU/L may be 
seen during the first trimester of pregnancy (due to hCG secretion), after 
treatment of hyperthyroidism (because TSH can remain suppressed for 
several months), and in response to certain medications (e.g., high doses 
of glucocorticoids or dopamine). Importantly, secondary hypothyroidism, 
caused by hypothalamic-pituitary disease, is associated with a 
variable (low to high-normal) TSH level, which is inappropriate for 
the low T4 level. Thus, TSH should not be used as an isolated 
laboratory test to assess thyroid function in patients with suspected 
or known pituitary disease. 
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 Autoimmune thyroid disease is detected most easily by measuring 
circulating antibodies against TPO and Tg. Because antibodies to Tg 
alone are uncommon, it is reasonable to measure only TPO antibodies. 
About 5–15% of euthyroid      women and up to 2% of euthyroid men 
have thyroid antibodies; such individuals are at increased risk of 
developing thyroid dysfunction. Almost all patients with autoimmune 
hypothyroidism, and up to 80% of those with Graves’ disease, have TPO 
antibodies, usually at high levels.  
 NUCLEAR IMAGING  
The thyroid gland selectively  transports radioisotopes of iodine 
(123I, 125I, 131I)  and 99mTc pertechnetate, allowing thyroid imaging 
and quantitation of radioactive tracer fractional uptake. Nuclear imaging 
of Graves’ disease is characterized by an enlarged  gland and increased 
tracer uptake that is distributed homogeneously. Toxic adenomas appear 
as focal areas of increased uptake, with suppressed tracer uptake in the 
remainder of the gland. In toxic MNG, the gland is enlarged—often with 
distorted architecture—and there are multiple areas of relatively increased 
(functioning nodules) or decreased tracer uptake (suppressed thyroid 
parenchyma or nonfunctioning nodules). Subacute, viral, and postpartum 
thyroiditis are associated with very low uptake because of follicular cell 
damage and TSH suppression. 
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Thyroid Ultrasound  
Ultrasonography is valuable for the diagnosis and evaluation  of  
patients  with  nodular  thyroid  disease. . Using 10- to 12-MHz linear 
transducers, resolution and image quality are excellent, allowing the 
characterization of nodules and cysts >3 mm. Certain sonographic 
patterns are highly suggestive of malignancy (e.g., hypoechoic solid 
nodules with infiltrative borders and micro calcifications), whereas other 
features correlate with benignity (e.g., spongiform nodules defined as 
those with multiple small internal cystic areas)  
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CKD AND THYROID 
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THYROID FUNCTIONS IN CHRONIC RENAL FAILURE 
Various studies of thyroid function in uremic patients have been 
carried out which have shown various conflicting results. 
Hypothyroidism, hyperthyroidism and euthyroid state have all been 
reported by various workers. CKD is associated with a higher 
prevalence of primary hypothyroidism both overt and sub clinical, but 
not with hyperthyroidism. In fact the prevalence of primary 
hypothyroidism, mainly in the sub clinical form, increases as GFR 
decreases. Most of the patients are euthyroid because of circulating 
free thyroid hormone levels. Thyroid hormone levels in CKD Serum 
triiodothyronine levels were consistently found to be low without any 
regard to treatment of CRF. Thyroid function studies conducted in 
clinically euthyroid uremic dialysis patients demonstrate decrease 
levels of triiodothyronine. 
Effect of Hemodialysis on thyroid function 
The thyroid function studies on patients with CRF before and 
after hemodialysis resulted in only slight increase in TT3 
concentration without significant change in other thyroid function. A 
study on thyroid function in uremic patients with conservative 
management and with regular dialysis was done and they found that 
there is no change in thyroid profile except decrease in TSH in 
hemodialysates compare to normals. Chronic renal failure is one 
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among the condition causing low syndrome. As with other low T3 
syndromes, CRF produces decrease in T3 when GFR falls below 50%. 
There is marked decrease of T3 than T4 as the GFR deceases. In 
ESRD, on average, diminished T4 is found in 29% of the patients and 
diminished T3 in 55% of the patients.  
CRF as low T3 syndrome differs from other conditions causing 
similar illness, by two unique features. 
1. rT3 is usually low or normal in CRF due to redistribution into the 
extravascular compartment. 
2. Increased incidence of goiter is present in CRF, probably due to 
decreased clearance of iodine by the kidney. 
Despite decreased circulating T4 and T3, thyroid stimulating 
hormone (TSH) level in serum is not elevated. This absence of TSH 
elevation is not due to dysfunction of hypothalamo-pituitary axis, 
because truly hypothyroid renal failure patients can mount a high TSH 
response. 
Thyroid hormone losses during hemodialysis and peritoneal 
dialysis are trivial and do not require replacement. Thus multitude of 
defects at all levels of hypothalamo-pituitarythyroid-peripheral axis 
does seem to exist in uremia. Dialysis therapy minimally affects 
thyroid hormone metabolism while Zinc, Erythropoietin 
administration may partially reverse these abnormalities. 
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Thyroid hormone metabolism normality’s with renal 
transplantation. Goiter and hypothyroidism may be induced by iodide 
excess due to reduced iodide excretion by the kidneys. 
PATHOPHYSIOLOGY OF LOW T3 SYNDROME 
In CKD, there is initial decrease in total T3, later T4 despite 
normal or low TSH. Various mechanisms have been proposed for the 
change in Thyroid profile. According to the postulates, CKD affect 
thyroid at all levels. 
A. Change in Hypothalamic – pituitary – thyroid axis 
1. Sensitivity of TSH secretion to low thyroid hormone is 
decreased. 
2. Limited TSH reserve. 
3. Due to changes in thyrotrophs or to decreased TRH secretion, 
as manifested by decrease in nocturnal pulses of TSH secretion. 
4. Tissue concentration of the hormone may be appropriate for the 
patient, so the patient is in euthyroid state. 
5. Serum FT3 and FT4 appears normal by sensitive methods. 
B. Changes in hormone Transport 
1. Presence of protein and non-protein inhibitors preventing the 
binding of thyroxin with thyroxin binding protein. Non-protein 
inhibitor is non-esterified unsaturated fatty acid. 
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2. Acquired intrinsic structural alternation in the T4 binding site. 
3. Decrease in concentration of thyroxin binding globulin. 
C. Changes in metabolism 
1. Decrease in the activity of lodothyronine 5 – Deiodinase 
leading to lowT3 
2. Increase in Non-deiodinative pathways of iodothyronine 
degradation leading to increased serum T3 sulphate, 
diiodotyrosine, triiodothyroacetic acid and tetraiodothyroacetic 
acid. As previously stated, there is no increase in rT3 in CRF 
due to redistribution rT3 into extra vascular compartment. 
D. Changes in plasma membrane Transport: 
T3 and T4 may enter cells not only by diffusion but also by 
active energy dependent transport across plasma membrane. 
Accumulation of the following substances prevents uptake and 
subsequent deiodination. a)3 – carboxy 4 – methyl 5 – propyl 2 – 
Furane (CMPF) b)Indoxyl sulphate Complications of CKD worsened 
by coexisting hypothyroidism are, 
I.Cardiovascular complications 
a) Secondaryhypertension 
b)  LV failure and pulmonary edema 
c)  Accelerated atherosclerosis 
d)  Myocardial infarction 
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e) Pericarditis 
f) Uremic cardiomyopathy 
g) Hypothyroidism is usually associated with elevated LDL-c 
levels due to a reduction in hepatic LDL receptor formation 
and delayed clearance of LDL. 
II. CNS and neuromuscular complications: 
Dementia 
Uremic encephalopathy 
Peripheral neuropathy  
Proximal muscle weakness 
III. Hematological complications like anemia 
Hypothyroidism can cause normocytic normochromic, macrocytic 
anemia or iron deficiency (microcytic) anemia due to menorrhagia. 
IV. Electrolyte imbalance like hyponatremia 
Hypothyroidism can cause euvolemic hypoosmolar 
hyponatremia. The occurrence of hyponatremia with hypothyroidism 
generally suggests severe disease, including myxedema coma. 
V. Fluid overload – edema 
Myxedema may worsen pre-existing volume overload state of 
CRF. 
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VI. Effects on Vascular System: 
1. Increased Systematic Vascular Resistance (SVR) 
2. Increased arterial stiffness as indicated by increased brachial 
ankle 
pulse wave velocity 
3. Endothelial dysfunction because of impaired Nitric Oxide (NO) 
availability. 
4.  All these factors predispose to diastolic HTN. 
In a study by ‘Micel Choncole et al”6 showed among 3089 
adult participants, 9.5% had subclinical primary hypothyroidism and 
9% had an estimated GFR >60 ml/min per 1.73 m2. Compared with 
participants with an estimated GFR >60 ml/min per 1.73 m2, those 
with estimated GFR <60 ml/min per 1.73 m2 had an increased odds of 
subclinical primary hypothyroidism after adjusting for age, gender, 
fasting plasma glucose, total cholesterol, and triglyceride 
concentrations. 
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DIAGNOSIS OF PRIMARY THYROID DISEASES IN CKD 
Recent studies have shown the prevalence of hypothyroidism is 
increased in chronic renal failure, and also several clinical features of 
both hypothyroidism and chronic renal failure are similar, so 
differentiating both the conditions on clinical back ground is less 
likely. Hence, all the CRF patients with symptoms of hypothyroidism 
should be screened for hypothyroidism 
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MATERIALS AND METHODS 
 
STUDY POPULATION: 
               The study will be conducted on 50 consecutive adult                 
(age≥18 years) CKD patients attending outpatient and inpatient 
department of Government Rajaji Hospital & Madurai Medical 
College during the study period. 
INCLUSION CRITERIA: 
Non diabetic chronic kidney disease patients of various etiology as 
diagnosed by biochemical and radiological investigations. 
EXCLUSION CRITERIA:  
Patients with  
               1) Thyroid treatment  
               2) Diabetes 
               3) concurrent treatment with lithium, amiodarone or iodin 
DESIGN OF STUDY: 
Prospective study 
PERIOD OF STUDY: 
May  2018 To October 2018 ( 6 months) 
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METHODOLOGY: 
50 CKD pts stage 1 – 4 (MDRD), >18 yrs, non DM ; ANA -ve , elev. 
TSH 
↓ 
start levothyroxine 25 – 50 microg/d 
↓ 
repeat T3,T4, TSH, urea and creatinine after 3 months 
↓ 
titrate thyroxine dose to maintain TSH below lower 
half of reference range 
↓ 
repeat after 3 months 
 
 
 LABORATORY INVESTIGATIONS: 
                  Blood urea 
                  Serum creatinine  
                  Fasting and postprandial blood sugar 
                  Thyroid stimulating hormone  
                  Free thyroxine  
                  Free triiodothyronine  
                  Anti nuclear antibody  
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                  Serum uric acid  
                  Urine albumin and sugar 
RADIOLOGICAL INVESTIGATION 
                Ultrasound abdomen and pelvis  
COLLABORATING DEPARTMENTS: 
Department of  Nephrology 
Department of Endocrinology 
Department of  Biochemistry 
Department of  Radiology 
ETHICAL CLEARANCE: Clearance obtained 
CONSENT: Individual written and informed consent obtained. 
STATISTICAL ANALYSIS:  
All data were entered in Excel 2007 and statistical analysis was 
performed using the statistical software SPSS 16.0.Data were 
expressed as frequency (with percentages), median values (with range 
(min, max)). For continuous variables, Mann Whitney U-test was 
performed to find the differences between two groups and for 
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RESULTS AND OBSERVATIONS 
TABLE 1- COMPARISSION OF SEX 
                                                   
 
 
 
 
 
 
 
 
 
 
 
 
60
40
SEX
MALE
SEX MALE FEMALE 
NO 30 20 
PERCENTAGE 60 40 
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TABLE 2 - COMPARISSION OF AGE 
 
S.NO AGE (years) PERSON 
1 <20 0 
2 20 – 29 5 
3 30 – 39 8 
4 40 – 49 20 
5 50 – 59 9 
6 >59 8 
 
 
 
 
 
0
5
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AGE
<20 20-29 30-39 40-49 50-59 >59
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TABLE - 3 MEAN TSH COMPARISION 
 
S.NO DURATION MEAN S.D. SIGNIFICANCE 
1 BASELINE 7.28 1.06 <.001 
2 3rd MONTH 6.47 1.01 <.001 
3 6th MONTH 6.06 0.94 <.001 
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TABLE - 4 MEAN UREA COMPARISION 
 
S.NO DURATION MEAN S.D. SIGNIFICANCE 
1 BASELINE 74.72 21.64 <.001 
2 3rd MONTH 67.34 19.17 <.001 
3 6th MONTH 62.20 17.51 <.001 
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TABLE - 5 MEAN CREATININE COMPARISION 
 
S.NO DURATION MEAN S.D. SIGNIFICANCE 
1 BASELINE 2.33 0.71 <.001 
2 3rd MONTH 2.03 0.61 <.001 
3 6th MONTH 1.92 0.59 <.001 
 
 
 
 
 
 
 
 
 
0
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TABLE 6 – MEAN eGFR COMPARISION 
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BASELINE 3rd MONTH 6th MONTH
32.16
37.97 40.21
DURATION
MEAN eGFR
eGFR
S.NO. DURATION MEAN S.D. SIGNIFICANCE 
1 BASELINE 32.16 10.75 <.001 
2 3rd MONTH 37.97 12.84 <.001 
3 6th MONTH 40.21 13.30 <.001 
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DISCUSSION 
 
  Even though previous studies have demonstrated that 
restoration of euthyroidism has beneficial effects on cardiac dysfunction 
in patients with SCH, the impact of THRT on renal function has not been 
extensively explored in these patients. The results of this study show that 
thyroid hormone treatment significantly abrogated the decrease in eGFR 
in CKD patients with SCH.  
The data of 14,623 adult participants from the third National 
Health and Nutrition Examination Survey, a nationally representative 
sample of the United States population, revealed that the prevalence of 
hypothyroidism increased with lower levels of GFR, occurring in 10.9% 
of patients with stage 2 CKD, 21.0% with stage 3 CKD, and 23.1% with 
stage 4 or 5 CKD. Moreover, Chonchol M et al. showed that the 
prevalence of SCH increased from 7% at an eGFR 90 mL/min/1.73 m2 to 
17.9% at an eGFR <60 mL/min/1.73 m2 in 3,089 unselected outpatient 
adults. Similarly in our study, the prevalence of hypothyroidism increased 
with declining levels of eGFR occurring in 3.1% of cases with stage 3b 
CKD, 25% cases with stage 4, and 71.9% of cases with stage 5 or end-
stage renal disease. The incidence of hypothyroidism is up to 4/1000 
women and 1/1000 men and the prevalence of OH increases with age. 
SCH is found in 6–8% of women (10% over the age of 60yrs) 
  
73 
 
and 3% of men. This clearly demonstrates the higher prevalence of 
hypothyroidism in patients with chronic renal dysfunction. The effect of 
thyroid hormone replacement on renal function has not been widely 
investigated in hypothyroid CKD patients, especially in SCH. A recent 
study by Shin et al. demonstrated that thyroid hormone treatment not only 
preserved renal function but was also an independent predictor of renal 
outcome. However, they compared changes in eGFR in two different 
study populations. Thus, to clarify the direct impact of thyroid hormone 
treatment on the decline in renal function, it was imperative to compare 
decline in eGFR before and after L-thyroxine replacement in the same 
patient.  
The results of this study showed that THRT significantly improved 
the renal function as evidenced by mean eGFR (ml/min/1.73 m2) which 
increased from 32.16 ± 10.75 to 37.97 ± 12.84 and 40.21 ± 13.30 after 3 
and 6 months of THRT, respectively (P < 0.001). 
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CONCLUSION 
 
Thyroid hormone replacement for subclinical hypothyroidism may 
improve estimated glomerular filtration rate in chronic kidney disease 
patients. Thyroid hormone therapy may preserve renal function better in 
chronic kidney disease patients with subclinical hypothyroidism. 
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SUMMARY 
 
 A prospective study was done at Government Rajaji Hospital, 
Madurai among 50 chronic kidney disease patients for assessing the 
impact of thyroid hormone replacement in subclinical hypothyroidism. 
From the present study, Thyroid hormone replacement for subclinical 
hypothyroidism may improve estimated glomerular filtration rate in 
chronic kidney disease patients. Thyroid hormone therapy may preserve 
renal function better in chronic kidney disease patients with subclinical 
hypothyroidism. 
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 PROFORMA 
Name: 
Age/ Sex: 
Occupation: 
Presenting complaints:        
   
Past history: 
        H/O Diabetes, Systemic Hypertension, Coronary artery disease,  
        H/O thyroid disease in the past 
        H/O drug intake in the past 
Personal history 
       H/O Alcohol consumption 
General Examination 
 
Vitals 
BP 
Pulse rate 
RR 
SpO2 
 
 
 
 System Examination 
CVS: 
RS: 
Abdomen: 
CNS: 
                                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 LIST OF ABBREVIATION 
 
GFR     :  Glomerular Filtration Rate 
ESRD   : End Stage Renal Disease 
CKD     :  Chronic Kidney Disease 
ESA      :  Erythropoiesis Stimulating Agent 
PCR      : Protein Creatinine Ratio 
DM      : Diabetes Mellitus 
TBG     : Thyroxine Binding Globulin 
TTR      : Transthyretin  
TSH      : Thyroid Stimulating Hormone 
TRH     :  Thyrotropin Releasing Hormone 
 
 
 
                                      
 
 
 
 
 
 
 MASTER CHART 
 
AGE SEX 
eGFR 
0 
eGFR 
3 
eGFR 
6 
TSH 
0 
TSH 
3 
TSH 
6 
UREA 
0 
UREA 
3 
UREA 
6 
CREA 
0 
CREA 
3 
CREA 
6 
46 1 22.34 24.06 26.06 7.8 6.1 5.3 78 70 64 3.2 3 2.8 
51 1 16.43 19.09 19.73 6.4 5.4 5 83 78 72 4.1 3.6 3.5 
42 1 30.25 37 39.14 7.2 6.2 5.7 48 46 40 2.5 2.1 2 
43 2 27.32 34.86 37.39 6.2 5.1 4.8 54 50 52 2.1 1.7 1.6 
48 1 20.65 23.86 23.86 5.8 5.1 4.8 82 70 68 3.4 3 3 
61 1 46.94 54.76 59.65 8.1 6.1 5.9 48 44 40 1.6 1.4 1.3 
57 2 24.45 25.8 27.3 8.6 7.5 6.5 58 56 50 2.2 2.1 2 
38 1 33.99 37.76 39.94 7.6 6.5 5.8 69 54 40 2.3 2.1 2 
32 1 37.05 46.71 53.51 7.2 6.1 6 74 60 59 2.2 1.8 1.6 
46 2 39.73 51.4 51.4 6.6 5.4 5.2 48 40 38 1.5 1.2 1.2 
33 1 19.02 23.06 25.74 6.3 6.1 5.8 127 114 100 3.9 3.3 3 
28 2 33.46 40.79 43.95 7.4 7 7 76 68 65 1.9 1.6 1.5 
43 1 28.78 31.56 31.56 9.8 9.6 9.3 88 83 80 2.6 2.4 2.4 
46 1 49.71 57.99 53.55 7.2 6.8 6.5 72 68 66 1.6 1.5 1.5 
40 1 26.81 30.55 32.03 6.8 6.2 6 110 105 97 2.8 2.5 2.4 
38 2 19.3 22.91 24.01 5.9 5.5 5.2 88 73 70 2.9 2.5 2.4 
62 2 26.83 30.3 34.71 8.6 8.3 8 93 88 72 2 1.8 1.6 
54 1 42 48.12 51.84 7.4 7.2 6.8 94 90 85 1.8 1.6 1.5 
58 1 48.12 55.32 55.32 8.1 7.8 7.5 60 48 40 1.5 1.4 1.4 
59 1 26.99 29.6 32.72 6.3 5.9 5.5 78 76 70 2.6 2.4 2.2 
43 2 25.89 28.9 32.64 6.1 5.8 5.7 64 60 58 2.2 2 1.8 
56 2 31.05 35.57 38.18 5.8 5.5 5.5 56 50 40 1.8 1.6 1.5 
65 1 40.08 49.47 49.47 7.4 7 6.4 52 48 45 1.8 1.5 1.5 
43 1 34.89 38.95 38.95 7.1 6.9 6.5 70 68 57 2.2 2 2 
24 2 34.52 42.09 39.25 6.8 6.5 6.3 63 55 86 1.9 1.9 1.7 
63 1 34.07 38.24 40.17 6.3 6 5.7 99 86 78 2.1 1.9 1.8 
65 1 15.77 17.8 19.02 5.9 5.4 5.3 103 89 76 4 3.6 3.4 
49 2 19.91 23.95 25.21 6.2 5.9 5.2 63 58 55 2.7 2.3 2.2 
36 2 31.79 36.15 41.76 8.1 7.8 7.5 59 58 46 1.9 1.7 1.5 
24 1 52.89 61.11 66.18 9.2 9 8.2 49 46 45 1.7 1.5 1.4 
30 2 43.34 51.12 56.06 6.6 6.3 6.1 44 43 40 1.5 1.3 1.2 
36 2 19.52 23.16 24.28 7.3 7 5.9 93 90 75 2.9 2.5 2.4 
45 1 26.18 29.81 32.85 5.8 5.2 5 85 78 60 2.8 2.5 2.3 
40 1 20.72 24.76 25.74 6 5.5 5.1 130 110 98 3.5 3 2.9 
65 1 37.77 46.05 44.61 7.1 5.6 5 38 36 35 1.9 1.6 1.5 
48 2 28.26 34.09 39.39 6.5 5.8 4.9 56 48 44 2 1.7 1.5 
27 1 36.43 42.81 42.81 8.6 7.5 6.4 77 73 86 2.3 2 2 
36 1 52.24 60.95 60.95 8.2 6.1 5.8 66 53 50 1.6 1.4 1.4 
42 1 59.07 70.57 70.57 8 6.2 6 72 60 51 1.4 1.2 1.2 
 43 1 41.33 50.39 54.29 7.1 5.8 5.5 61 55 52 1.9 1.6 1.5 
60 1 47.1 59.85 65.64 6.2 5.8 5.5 66 53 50 1.6 1.3 1.2 
58 2 24.37 30.72 47.42 7.1 6.4 6.6 78 76 70 2.2 1.8 1.6 
56 2 20.24 25.89 27.39 8.3 6.2 6 88 84 76 2.6 2.1 2 
62 2 19.67 24.61 26.72 6.4 5.6 5.5 103 97 80 3.4 2.8 2.6 
49 2 19.89 28.02 21.76 7.6 6.1 5.7 118 86 73 3.5 2.6 2.5 
47 2 28.39 30.12 34.24 8.2 7.3 7.2 92 88 86 2 1.9 1.7 
40 1 24.76 30.55 33.64 9.6 8.1 6.6 90 76 68 3 2.5 2.3 
56 1 41.69 47.76 51.45 8 6.2 5.9 66 63 64 1.8 1.6 1.5 
40 2 33.12 40.88 40.88 8.3 7.1 6.3 64 57 58 1.8 1.5 1.5 
26 1 43.14 48.72 55.81 9.2 8 7.1 43 42 40 2 1.8 1.6 
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